Dr. Serrano on the Rationale for the INVICTUS Trial in Advanced GIST

Video

César Serrano-García, MD, discusses the rationale for the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

César Serrano-García, MD, principle investigator, Translational Sarcoma Research Program, faculty member, Sarcoma Unit, Vall d’Hebron Hospital, Barcelona, Spain, discusses the rationale for the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors (GIST).

Of more than 70 sarcoma subtypes, GIST is the most common, according to Serrano-García. Additionally, GIST is associated with KIT and PDGFRα oncogenic driver mutations that can be targeted with approved agents such as imatinib (Gleevec), sunitinib (Sutent), and regorafenib (Stivarga).

However, patients often progress on these agents, adds Serrano-García. Results from the INVICTUS trial demonstrated an 85% reduction in the risk of disease progression or death with the novel, oral KIT and PDGFRα TKI ripretinib (Qinlock) compared with placebo in heavily pretreated patients with advanced GIST.

The findings led to the May 15, 2020 FDA approval of ripretinib for use in patients with advanced GIST who have received prior treatment with 3 or more kinase inhibitor therapies including imatinib.


Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS